nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2011-342nnp-102Research ArticleORIGINAL INVESTIGATIONSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИPharmacoeconomic analysis of the use of movalis (meloxicam) in patients with nonspecific back painФармакоэкономический анализ применения мовалиса (мелоксикам) у больных с неспецифической болью в спинеГерасимоваО. Н.GerasimovaO. N.

Москва

Moscow

info@ima-press.netПарфеновВ. А.ParfenovV. A.

Department of Nervous Diseases

vladimirparfenov@mail.ruПоликлиника №6 ЗАО «Медицинские услуги»РоссияZAO “Medical Services”, Polyclinic SixRussian FederationКафедра нервных болезней Первого МГМУ им. И.М. СеченоваРоссияI.M. Sechenov First Moscow State Medical UniversityRussian Federation20111412201134NO4 (2011)2732Copyright © Gerasimova O.N., Parfenov V.A., 20112011Герасимова О.Н., Парфенов В.А.Gerasimova O.N., Parfenov V.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/102

The paper analyzes the use of movalis (meloxicam) in 150 patients with nonspecific back pain in the outpatient setting. Movalis was given in a single daily oral dose of 15 mg throughout the follow-up; the oral use of the drug was, if required, preceded by a 3-day course of its intramuscular administration (15 mg). The mean cost of treatment (medical services + pharmacotherapy) was 6670 rbl. (range 4601—9479 rbl.) in the entire group, 6074 rbl. (range 4367—8156 rbl.) in the acute subgroup (n = 112), 8951 rbl. (range 6662—10195 rbl.) in the subacute pain (n = 20), and 9904 rbl. (range 5436—12070 rbl.) in the chronic pain group (n= 18). In patients with subacute and chronic pain as compared to those with acute pain, the cost of treatment was 2121 rbl. (95% CI, 698 to 4744) and 2817 rbl. (95% CI, 701 to 4932) higher, respectively, during much longer treatment. Comparison of the cost of drug therapy and common practice involving manual therapy has demonstrated the benefits of movalis treatment.

Представлен анализ применения препарата мовалис (мелоксикам) у 150 больных с неспецифической болью в спине в амбулаторных условиях. Мовалис назначали перорально по 15 мг 1 раз в сутки в течение всего периода наблюдения, при необходимости пероральному приему предшествовал 3-дневный курс внутримышечного введения препарата (15 мг). Средние затраты на лечение (медицинские услуги + фармакотерапия) в общей группе больных составили 6670 руб. (4601; 9479), в подгруппе больных с острой болью (n=112) – 6074 руб. (4367; 8156), с подострой болью (n=20) – 8951 руб. (6662;10 195), с хронической болью (n=18) – 9904 руб. (5436; 12 070). Стоимость лечения больных с подострой и хронической болью по сравнению с таковой у больных с острой болью была выше на 2721 руб. (95% ДИ 698–4744) и 2817 руб. (95% ДИ 701–4932) соответственно при существенно более продолжительном сроке лечения. Сопоставление стоимости медикаментозного лечения и распространенной практики, включающей мануальную терапию, продемонстрировало преимущество лечения мовалисом.

боль в спинемелоксикамфармакоэкономический анализback painmeloxicampharmacoeconomic analysisReferences<div><p>Deyo R.A., Mirza S.K., Martin B.I. Back pain prevalence and visit rates: estimates from U.S. national surveys, 2002. Spine (Phila Pa 1976) 2006;31:2724-7.</p><p>Walker B.F. The prevalence of low back pain: a systematic review of the literature from 1966 to 1998. J Spinal Disord 2000;13:205-17.</p><p>Volinn E. The epidemiology of low back pain in the rest of the world. A review of surveys in low- and middle-income countries. Spine (Phila Pa 1976). 1997;22:1747-54.</p><p>Louw Q.A., Morris L.D., Grimmer-Somers K. The prevalence of low back pain in Africa: a systematic review. BMC Musculoskelet Disord 2007;8:105.</p><p>Schiњttz-Christensen B., Nielsen G.L., Hansen V.K. et al. Long-term prognosis of acute low back pain in patients seen in general practice: a 1-year prospective follow-up study. Fam Pract 1999;16:223-32.</p><p>Dagenais S., Caro J., Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J 2008;8:8-20.</p><p>Tramеr M.R., Moore R.A., Reynolds D.J. et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000;85:169-82.</p><p>Rubinstein S.M., van Middelkoop M., Assendelft W.J. et al. Spinal manipulative therapy for chronic low-back pain. Cochrane Database Syst Rev 2011;2:CD008112.</p><p>Van Tulder M., Malmivaara A., Hayden J. et al. Statistical significance versus clinical importance: trials on exercise therapy for chronic low back pain as example. Spine (Phila Pa 1976) 2007;32:1785-90.</p><p>Chen Y.F., Jobanputra P., Parton P. et al. Cyclooxygenase-2 selective non-steroidal antiinflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteorthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Asses 2008;12:11.</p><p>Russo R.B. Diagnosis of low back pain: role of imaging studies. Clin Occup Environ Med 2006;5:571-89.</p><p>Подчуфарова В.Я., Яхно Н.Н. Боль в спине. М.: ГЭОТАР-Медиа, 2010;368 с.</p><p>Герасимова О.Н., Парфенов В.А. Ведение пациентов с болью в спине в амбулаторной практике. Неврол нейропсихиатр психосом 2010;4:65-71.</p><p>Langman M.J., Kahler K.H., Kong S.X. et al. Use of gastroprotective agents and other healthcare resources among patients on nonsteroidal anti-inflammatory drugs in the United Kingdom. The 12th EULAR Congress. Glasgow, 6-11 June, 1999.</p></div><br /><div><p>Deyo R.A., Mirza S.K., Martin B.I. Back pain prevalence and visit rates: estimates from U.S. national surveys, 2002. Spine (Phila Pa 1976) 2006;31:2724-7.</p><p>Walker B.F. The prevalence of low back pain: a systematic review of the literature from 1966 to 1998. J Spinal Disord 2000;13:205-17.</p><p>Volinn E. The epidemiology of low back pain in the rest of the world. A review of surveys in low- and middle-income countries. Spine (Phila Pa 1976). 1997;22:1747-54.</p><p>Louw Q.A., Morris L.D., Grimmer-Somers K. The prevalence of low back pain in Africa: a systematic review. BMC Musculoskelet Disord 2007;8:105.</p><p>Schiњttz-Christensen B., Nielsen G.L., Hansen V.K. et al. Long-term prognosis of acute low back pain in patients seen in general practice: a 1-year prospective follow-up study. Fam Pract 1999;16:223-32.</p><p>Dagenais S., Caro J., Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J 2008;8:8-20.</p><p>Tramеr M.R., Moore R.A., Reynolds D.J. et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000;85:169-82.</p><p>Rubinstein S.M., van Middelkoop M., Assendelft W.J. et al. Spinal manipulative therapy for chronic low-back pain. Cochrane Database Syst Rev 2011;2:CD008112.</p><p>Van Tulder M., Malmivaara A., Hayden J. et al. Statistical significance versus clinical importance: trials on exercise therapy for chronic low back pain as example. Spine (Phila Pa 1976) 2007;32:1785-90.</p><p>Chen Y.F., Jobanputra P., Parton P. et al. Cyclooxygenase-2 selective non-steroidal antiinflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteorthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Asses 2008;12:11.</p><p>Russo R.B. Diagnosis of low back pain: role of imaging studies. Clin Occup Environ Med 2006;5:571-89.</p><p>Подчуфарова В.Я., Яхно Н.Н. Боль в спине. М.: ГЭОТАР-Медиа, 2010;368 с.</p><p>Герасимова О.Н., Парфенов В.А. Ведение пациентов с болью в спине в амбулаторной практике. Неврол нейропсихиатр психосом 2010;4:65-71.</p><p>Langman M.J., Kahler K.H., Kong S.X. et al. Use of gastroprotective agents and other healthcare resources among patients on nonsteroidal anti-inflammatory drugs in the United Kingdom. The 12th EULAR Congress. Glasgow, 6-11 June, 1999.</p></div><br />

The authors declare that there are no conflicts of interest present.